VJHemOnc is committed to improving our service to you

ASH 2019 | Gemtuzumab-based induction regimens produce higher rates of MRD negativity in CBF-AML

VJHemOnc is committed to improving our service to you

Jeffrey Lancet

Jeffrey Lancet, MD, Moffitt Cancer Center, Tampa, FL, discusses the study describing overall responses after standard inductions with high dose daunorubicin (90mg/m2) vs standard dose daunorubicin (60mg/m2) with gemtuzumab ozogamicin (GO) in favorable risk acute myeloid leukemia (AML). Incorporation of GO to 7+3 with standard dose daunorubicin resulted in comparable remission rates to 7+3 with high dose daunorubicin. Importantly, GO-based regimens produce higher rates of MRD negativity compared to 7+3 with high dose daunorubicin in CBF AML. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter